Corporate
2026.02.20
LUMOSA's Novel Stroke Drug LT3001 Clears FDA Review
Opening the Door to a $10.6 Billion Market Opportunity
Corporate
2026.02.07
LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE
Corporate
2026.01.06
Dr. Devlin to Present LT3001 Trial Results at ISC26
Corporate
2025.11.28
Lumosa has received the FDA’s feedback from the Type C consultation
The Company submitted a Type C meeting request to the U.S. Food and Drug Administration (FDA) for LT3001, its investigational therapy for acute ischemic stroke, based on the existing nonclinical data and clinical trial results.
Corporate
2025.11.28
Lumosa Has Received Feedback for the Type C Consultation from the US FDA
The Company submitted a Type C meeting request to the US FDA for LT3001, a novel therapy for acute ischemic stroke, based on the existing nonclinical data and clinical trial results.
Corporate
2025.11.04
Beach Cleanup!